News

Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment ...
Shares of Soleno Therapeutics Inc. (NASDAQ:SLNO) declined 3.7% after the company priced its previously announced public ...
Soleno Therapeutics's previously-announced public offering of 2.35 million shares was priced at $85 apiece, resulting in $200 million in proceeds. The biopharmaceutical company said on Thursday that ...
Preliminary quarterly sales figures for Vykat surpassed Wall Street estimates, but shares fell on concerns the company may ...
Next month will be the first opportunity to gauge the commercial launch of a new treatment for Prader-Willi syndrome, a rare ...
Soleno Therapeutics ( NASDAQ: SLNO) shares fell nearly 10% premarket on Thursday after the company proposed an offering of $200 million of shares of its common stock. In addition, the ...
Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases ...
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...
Soleno Therapeutics, Inc. (SLNO) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...
Soleno Therapeutics, Inc. has secured a loan and security agreement with Oxford Finance LLC for up to $200 million, aiming to enhance its financial standing for the anticipated commercial launch ...
Soleno Therapeutics, Inc. has announced positive results from its clinical program for VYKAT™ XR (diazoxide choline) extended-release tablets, aimed at treating hyperphagia in individuals with ...
Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the ...